Investing.com - LAVA Therapeutics NV reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
LAVA Therapeutics NV announced earnings per share of $-0.31 on revenue of $468K. Analysts polled by Investing.com anticipated EPS of $-0.6002 on revenue of $500K.
LAVA Therapeutics NV shares are down 72% from the beginning of the year, still down 70.64% from its 52 week high of $8.38 set on October 13, 2021.
LAVA Therapeutics NV follows other major Healthcare sector earnings this month
LAVA Therapeutics NV's report follows an earnings beat by Medtronic on August 23, who reported EPS of $1.13 on revenue of $7.37B, compared to forecasts EPS of $1.12 on revenue of $7.22B.
Merck ADR had beat expectations on Friday with third quarter EPS of $0.5392 on revenue of $5.69B, compared to forecast for EPS of $0.5165 on revenue of $5.57B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar